|
ATCC
mastocytoma cell line p815 Mastocytoma Cell Line P815, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/p815/P815/10__1128_slash_jvi__02298___16-46-52-56 Average 96 stars, based on 1 article reviews
mastocytoma cell line p815 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
DSMZ
murine cell line p815 ![]() Murine Cell Line P815, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/p815/P-815/pm31959757-249-1-13 Average 93 stars, based on 1 article reviews
murine cell line p815 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
ATCC
mouse mastocytoma line p815 ![]() Mouse Mastocytoma Line P815, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/p815/P815%3B+Mastocytoma%3B+Mouse/pmc00110314-122-8-12 Average 94 stars, based on 1 article reviews
mouse mastocytoma line p815 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
p815 ![]() P815, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/p815/P815+Cell+Complete+Medium/pmc11099600-40-6-7 Average 92 stars, based on 1 article reviews
p815 - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
Pfizer Inc
p815 cells ![]() P815 Cells, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/p815/transfected+p815+cell+lines/pm12193714-68-1-7 Average 90 stars, based on 1 article reviews
p815 cells - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Japan SLC inc
p815-hcd20 ![]() P815 Hcd20, supplied by Japan SLC inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/p815/p815+hcd20/us11617765-314-3-19 Average 90 stars, based on 1 article reviews
p815-hcd20 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Mastocytosis Society
p815 ![]() P815, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/p815/p815/pmc05669937-78-19-1 Average 90 stars, based on 1 article reviews
p815 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Mimotopes
p815 cells ![]() P815 Cells, supplied by Mimotopes, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/p815/p815+cells/pmc03060027-69-28-50 Average 90 stars, based on 1 article reviews
p815 cells - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Charles River Laboratories
p815-ido1 cells ![]() P815 Ido1 Cells, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/p815/p815+cells/pm28557618-29-32-43 Average 90 stars, based on 1 article reviews
p815-ido1 cells - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Pasteur Institute
p815 cell line (mouse mastocytoma, h2d) ![]() P815 Cell Line (Mouse Mastocytoma, H2d), supplied by Pasteur Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/p815/cell+line+p815+cell+line/pmc04769599-10-0-16 Average 90 stars, based on 1 article reviews
p815 cell line (mouse mastocytoma, h2d) - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
JCRB Cell Bank
p815 cells ![]() P815 Cells, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/p815/p815+cells/pmc03697442-115-8-10 Average 90 stars, based on 1 article reviews
p815 cells - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Johns Hopkins HealthCare
mastocytoma line p815 ![]() Mastocytoma Line P815, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/p815/mastocytoma+line+p815/pm15322167-72-1-11 Average 90 stars, based on 1 article reviews
mastocytoma line p815 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Nature communications
Article Title: Distinctive phenotypes and functions of innate lymphoid cells in human decidua during early pregnancy.
doi: 10.1038/s41467-019-14123-z
Figure Lengend Snippet: Fig. 6 dNK responses triggered by activating KIR. a Representative XCL1 and CD107a staining by CyTOF in lineage negative (Lin−) CD56+ decidual cells co-expressing 1–3 Killer-cell immunoglobulin-like receptors (KIR) following a 6 h co-culture with K562 (n = 10). b Representative XCL1 and CD107a staining by mass cytometry in Lin-CD56+ cells co-expressing 1–3 KIR following 4 h stimulation by PMA plus ionomycin (n = 8). c Representative XCL1 staining by flow cytometry in Lin-CD56+KIR2DS4+ decidual cells co-expressing 1–3 additional KIRs following activation via P815 cells coated with anti-KIR2DS4 (n = 6). d Correlation of frequency of XCL1+Lin-CD56+ decidual cells and mean side scatter for the same subset (n = 20). Two-tailed p-value calculated for Pearson correlation coefficients. Two-tailed one-way ANOVA of matched data points with Tukey correction and 95% confidence level was used. *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source Data file.
Article Snippet: The
Techniques: Staining, Expressing, Co-Culture Assay, Mass Cytometry, Cytometry, Activation Assay, Two Tailed Test
Journal: Biomedical Reports
Article Title: Radiocontrast medium induces histamine release in association with upregulation of miR‑19a‑3p and miR‑362‑3p expression
doi: 10.3892/br.2024.1780
Figure Lengend Snippet: Cytotoxicity of ultravist in P815 cells. P815 cells were incubated with different doses of ultravist for 24 h and cell viability was measured by the CCK-8 test. * P<0.05 vs. control.
Article Snippet: The mouse mast cell cell line,
Techniques: Incubation, CCK-8 Assay, Control
Journal: Biomedical Reports
Article Title: Radiocontrast medium induces histamine release in association with upregulation of miR‑19a‑3p and miR‑362‑3p expression
doi: 10.3892/br.2024.1780
Figure Lengend Snippet: Mast cells could be activated by ultravist stimulation. P815 cells were stimulated with ultravist for 24 h; (A) histamine and (B) β-hexosaminidase were measured by ELISA. * P<0.05, ** P<0.01.
Article Snippet: The mouse mast cell cell line,
Techniques: Enzyme-linked Immunosorbent Assay
Journal: Biomedical Reports
Article Title: Radiocontrast medium induces histamine release in association with upregulation of miR‑19a‑3p and miR‑362‑3p expression
doi: 10.3892/br.2024.1780
Figure Lengend Snippet: miRNA expression profile of ultravist-stimulated mast cells. P815 cells were treated with 50 mg/ml ultravist for 24 h. miRNA from the control and ultravist treatment groups was extracted and analyzed by miRNA array. miRNA/miR, microRNA.
Article Snippet: The mouse mast cell cell line,
Techniques: Expressing, Control
Journal: Biomedical Reports
Article Title: Radiocontrast medium induces histamine release in association with upregulation of miR‑19a‑3p and miR‑362‑3p expression
doi: 10.3892/br.2024.1780
Figure Lengend Snippet: KEGG Pathway Analysis of ultravist-treated mast cells. P815 cells were stimulated with 50 mg/ml ultravist for 24 h. Subsequent KEGG pathway analysis of the mTOR signaling pathway revealed upregulation of genes related to (A) miR-19A-3p and (B) miR-362-3p, which are highlighted in red. KEGG, Kyoto Encyclopedia of Genes and Genomes; miRNA/miR, microRNA.
Article Snippet: The mouse mast cell cell line,
Techniques:
Journal: Biomedical Reports
Article Title: Radiocontrast medium induces histamine release in association with upregulation of miR‑19a‑3p and miR‑362‑3p expression
doi: 10.3892/br.2024.1780
Figure Lengend Snippet: miR-19a-3p and miR-362-3p could be upregulated by ultravist treatment. P815 cells were treated with different doses of ultravist and (A) miR-19a-3p and (B) miR-362-3p were detected by reverse transcription-quantitative PCR. * P<0.05, ** P<0.01. miRNA/miR, microRNA.
Article Snippet: The mouse mast cell cell line,
Techniques: Reverse Transcription, Real-time Polymerase Chain Reaction
Journal: Biomedical Reports
Article Title: Radiocontrast medium induces histamine release in association with upregulation of miR‑19a‑3p and miR‑362‑3p expression
doi: 10.3892/br.2024.1780
Figure Lengend Snippet: Network analysis of miRNA-target interactions in mast cells. P815 cells were stimulated with 50 mg/ml ultravist for 24 h, the predicted interactions between miR-19a-3p and miR-362-3p were analyzed and the key target genes-Aox1, Akap2, and Uba2l were highlighted in yellow. miRNA/miR, microRNA.
Article Snippet: The mouse mast cell cell line,
Techniques:
Journal: Oncotarget
Article Title: Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
doi: 10.18632/oncotarget.19970
Figure Lengend Snippet: Dilution series of crenolanib to treat HMC1.2 or p815 mastocytosis cell lines were set up and inhibition of cellular proliferation (A, B) or induction of apoptosis (C, D) was assessed. Samples were compared using one-way ANOVA and Tukey’s honestly significant difference (HSD) test. Values in black indicate significance compared to the untreated controls.
Article Snippet: Using
Techniques: Inhibition
Journal: Oncotarget
Article Title: Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
doi: 10.18632/oncotarget.19970
Figure Lengend Snippet: Isogenic Ba/F3 cells harboring a mutant-KIT D816V isoform ( A , left and mid panels), the corresponding mastocytosis cell line HMC1.2 (D816V+, A , right panel), Ba/F3 cells harboring a mutant-KIT D816Y isoform ( B , left panel) and the corresponding mastocytosis cell line p815 (murine D814Y, B, right panel) were treated with crenolanib or dasatinib (A) in dose-dilution assays for 90‘. Western immunoblots are shown for inhibition of autophosphorylation of KIT and consecutive downstream signaling via ERK1/2, STAT5 and AKT. Two different phospho-KIT antibodies (monoclonal Tyr703, 145 KDa, polyclonal Tyr719, 120/145 KDa) provide similar results via dephosphorylation of KIT (not degradation as indicated by stable KIT blots) upon crenolanib as well as dasatinib exposure. Tubulin serves as loading control.
Article Snippet: Using
Techniques: Mutagenesis, Western Blot, Inhibition, De-Phosphorylation Assay, Control
Journal: Oncotarget
Article Title: Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
doi: 10.18632/oncotarget.19970
Figure Lengend Snippet: HMC1.2 (A/B) or p815 (C/D) were sequentially treated with one or both agents and induction of apoptosis was assessed using an annexin V-based flow cytometry assay. (E) Validation in native mastocytosis patient samples (n=11) treated with 2-CDA followed by crenolanib (Cb). Reduction of the CD25+ viable cohort was assessed flow cytometrically. A normalized (untreated set as 1) dose-effect plot is shown. Significance of the combination compared to the monoagents is provided using Tukey Kramer test and Student’s t-test.
Article Snippet: Using
Techniques: Flow Cytometry, Biomarker Discovery
Journal:
Article Title: CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in-vitro expansion of viral specific CD8 + T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals
doi: 10.1016/j.vaccine.2008.05.018
Figure Lengend Snippet: CD40L expressed by recombinant ALVAC virus boosts the immunogenicity of an HIV-1 canarypox vaccine in mice. Female Balb/c mice of 6–8 wks age were immunized 3 times with an HIV-1 canarypox vaccine, vCP1452, with either of vCPmCD40L or vCPmSP-D-CD40L or ALVAC II. Six weeks after the last immunization, mice were sacrificed and spleens were taken and used for preparation of splenocytes. (A) IFN-γ ELISpot. Splenocytes were stimulated with P815 cells pulsed with an H-2Kd restricted HIV-1 Gag peptide, AMQMLKETI, for 16 hrs. Cells producing IFN-γ were detected and counted as described in Materials and Methods. (B) and (C) MHC-I tetramer analysis. Splenocytes were stained with anti-mouse CD8 mAb and AMQMLKETI/H-2Kd tetramer. (B) shows representative flow cytometry results for each group of mice. Numbers are percentage of tetramer positive cells in CD8+ cells. (C) shows summary of the tetramer data for each group of mice. (D) to (G) Polyfunctional CD8+ T cells analyzed by flow cytometry. Splenocytes were stained with anti-mouse IFN-γ and anti-mouse TNF-α mAbs and co-expressing cells are measured in (D) and (E) or anti-mouse IFN-γ and anti-mouse CD107a mAbs and co-expressing cells are measured in (F) and (G). (D) and (F) show representative flow cytometry results and (E) and (G) show summary of the polyfunctional CD8+ T cell data for each group of mice. (H) CD8+ T cells producing IFN-γ analyzed by flow cytometry. Splenocytes were stained with anti-mouse CD8 and anti-mouse IFN-γ mAbs. (I) and (J) Memory HIV-1-Gag specific CD8+ cells analyzed by flow cytometry. Splenocytes were stained with anti-mouse CD8, anti-mouse CD127 (IL-7Rα) mAbs, and AMQMLKETI/H-2Kd tetramer. In (I) CD8+/Tetramer+ cells are gated and measured by CD127 (y-axis). CD8+ T cells from naïve mice unstained for CD127 was used as control for CD127 gating. (J) shows summary data of CD127 expression in tetramer+ cells. (K) Lymphocyte proliferation. Splenocytes were stimulated with HIV-1 p24 Gag for 6 days and [3H]-thymidine incorporation was measured. (L) Cytokine production. Splenocytes were stimulated with HIV-1 p24 Gag for 5 days. IFN-γ and IL-4 in the supernatant were measured by ELISA. (M) Serum anti-Gag antibody. HIV-1 p24 Gag was used as antigen, and mice serum anti-Gag antibodies were measured by ELISA. Data shown are mean±SEM. n=4–10. *: P<0.05. **: P<0.01.
Article Snippet: The plates were then washed 3 times with PBS and blocked with R-10 medium (RPMI-1640 supplemented with 10% fetal bovine serum) for at least 2 h. Splenocytes and
Techniques: Recombinant, Virus, Immunopeptidomics, Enzyme-linked Immunospot, Staining, Flow Cytometry, Expressing, Control, Enzyme-linked Immunosorbent Assay